145 results on '"Perez, P"'
Search Results
2. EP.13A.03 A Phase II Study of Vobramitamab Duocarmazine in Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
3. P3.13C.06 Artificial Intelligence Meets SCLC - Integrating Clinicopathological and Whole-Slide Image Data for Prognostic Prediction in SCLC.
4. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
5. OA11.06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1
6. EP.17D.01 Trends in Lung Cancer Incidence Among Individuals Under 50: A Retrospective Analysis of the National Inpatient Sample (NIS) Database
7. P4.17D.04 Insights into Lung Cancer During Pregnancy: Analysis of the National Inpatient Database (NIS)
8. P4.15B.01 Remote Exercise Program for Patients with Lung Cancer on Immune Checkpoint Inhibitors
9. MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study
10. P4.15D.02 Risk of Osteoporosis and Bone Fracture by Systemic Therapy in Lung Cancer Survivors
11. EP1.12-26 Retrospective Study About the Impact of Brain Metastases and Cranial Irradiation in Small Cell Lung Cancer
12. EP1.12-29 Retrospective Study About Small Cell Lung Cancer: Our Experience in a Spanish Hospital
13. EP1.12-20 Retrospective Study About the Impact of Metastatic Site in Small Cell Lung Cancer
14. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
15. P2.03-01 Prevalence of EGFR Alterations in Chilean Lung Cancer Patients: A Retrospective Study
16. P07 Preliminary Orthogonal Analysis of EML4-ALK Gene Fusion Detection Methods in Chilean Patients with Lung Adenocarcinoma
17. PD.1.05 Molecular Characterization of EGFR Somatic Mutations in Lung Adenocarcinoma Tumors from Chilean Patients
18. PD.1.04 A Comprehensive Description of the Molecular Epidemiology of Somatic Mutations in Actionable Genes in NSCLC Chilean Patients
19. P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON
20. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
21. EP14.02-07 Atypical Response to Metronomic Chemotherapy in a Patient with Advanced Thymoma
22. EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC
23. EP10.01-15 Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer
24. Whole-Exome Profiling of NSCLC Among African Americans
25. The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer
26. PD.01.03 Genomic Landscape of Primary-Resistance to Osimertinib among Hispanic Patients With EGFR-Mutant Non-Small-Cell Lung Cancer: Results of an Observational Longitudinal-Cohort Study
27. PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients
28. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
29. P1.22-07 Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer
30. P1.21-02 Genetic Susceptibility to Immune Checkpoints Blockade Resistance
31. P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer
32. EP07.04-12 Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-Small Cell Lung Cancer
33. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose
34. P2.13-01 Low EV miR-30c Levels as Biomarker of Increased Tumor Autophagy and Chemoradiotherapy Resistance in Locally Advanced NSCLC
35. EP07.01-001 Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma
36. A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
37. 215P Assessment of patient and clinician awareness and clinical outcomes of changes in lifestyle habits during lung cancer treatment
38. 10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
39. PP.17 Stereotactic Ablative Radiotherapy in Oligometastatic Pulmonary Disease. First Institutional Experience
40. PP.04 EGFR Structure-Based Classification and Presence of Commutations in Peruvian Patients With Advanced Lung Cancer
41. PD.02.01 High Extracellular Vesicle TGF-β & PD-L1 Predict Poor Outcomes in Patients With Non-small Cell Lung Cancer Undergoing Immune-Checkpoint Inhibitors
42. EP01.03-008 Lung Cancer Screening Patients Experiences and Satisfaction: Quantitative and Qualitative Findings From a Survey Study
43. EP16.03-002 Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)
44. EP16.01-013 The Diagnostic Accuracy of Tumor Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis
45. P01.05 Pilot Study of Inhaled Azacitidine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
46. P33.15 TMB in the First-Line Setting of NSCLC: A Systematic Review with Indirect Comparisons Between PD-1 and PD-L1 Inhibitors
47. RETRACTED: Tumor Dependence on the EGFR Signaling Pathway Expressed by the p-EGFR:p-AKT Ratio Predicts Erlotinib Sensitivity in Human Non-small Cell Lung Cancer (NSCLC) Cells Expressing Wild-Type EGFR Gene
48. OA06.02 High-Grade Patterns Cause the Upstaging of Lung Adenocarcinomas From T1 to T2a: A Multicentric Analysis
49. P2.18 Sternal Cavernous Hemangioma and Anterior Thoracic Wall Reconstruction: Case Report
50. I.8 Re-thinking Access to Care
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.